Despite the clear association between FGF19 and HCC, the metabolic properties of the hormone, notably its remarkable inhibitory effect on lipid accumulation, have prompted efforts to develop analogs devoid of the oncogenic activity. The gene discussed is FGF19; the disease is hepatocellular carcinoma.